YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST: CONTROVERSIES IN PREVENTION AND MANAGEMENT OF ASCVD
324 - MISSED OPPORTUNITY FOR MISSED OPPORTUNITIES” PREVENTING RECURRENT EVENTS IN MY 46 YR. OBESE FEMALE ASCVD PATIENT (BMI 42) AND A1C 6.5
Saturday, October 26, 2024
10:15 AM – 10:30 AM PT
Room: 211
•“Inflammation controversies” I. hsCRP screening should be routine and what if elevated? II. Targeting inflammation: (a) Colchicine-“it works so why the therapeutic inertia?” (b) The future of IL-6 inhibitors III. MAFLD - “underappreciated” risk for ASCVD
•Management controversies - “I am short of breath” • Role of SGLT2i, GLP-1RA and GLP-1RA/GIP in obesity/ASCVD +/- diabetes • HFpEF-“foundation” therapies in 2024
Disclosure(s):
Subodh Verma, MD PhD FRCSC FAHA FCCS FCAHS: Amarin: Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Astrazeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Canadian Medical and Surgical Knowledge Translation Research Group: Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Humber River Health: Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); PhaseBio: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); S & L Solutions Event Management Inc: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Sun Pharma: Speaker/Honoraria (Ongoing)
